Articles by Benjamin Garmezy, MD
The final segment of this roundtable series addresses the future of immunotherapy combinations.
The fifth segment of this roundtable series focuses on the use of circulating tumor DNA (ctDNA) in managing bladder cancer.
In part four of this roundtable, the use of immunotherapy in the adjuvant setting for bladder cancer is discussed.
The third segment of this roundtable series focuses on the latest developments in bladder cancer treatments.
In part two of this roundtable, multidisciplinary approaches to managing MIBC are discussed.
The first segment of this roundtable series focuses on the latest developments in MIBC treatment, including the NIAGARA trial
In the final segment of this series, Drs. Morris, Garmezy, and Chen discuss the use of novel radiopharmaceuticals.
In the fourth part of this series, the panelists discuss barriers to the use of radium-223 and other radioligands.
In part 3 of this series, the panelists review the latest game-changing studies in prostate cancer and CRPC from ESMO 2024.
In the second part of this series, the decision-making process of considering ADT and doublet or triplet therapy is weighed.
In the first segment of this roundtable series, the panelists discuss the use of PSMA PET scans and ADT for CRPC.
Benjamin Garmezy, MD, discusses what the best treatment strategies may be for RCC and the potential of IO-only strategies.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.